Investors
News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 26, 2021
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today...
-
Mar 8, 2021Aridis Enters into APEX™ Licensing and Product Discovery Agreement for Zoonotic Viruses with Kermode
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an out-licensing and product discovery agreement with Kermode Biotechnologies, Inc. Kermode works on vaccines...
-
Feb 23, 2021National Institute of Allergy and Infectious Disease (NIAID) and the Coronavirus Immunotherapy Consortium (CoVIC) are providing preclinical services support to accelerate development
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced...
-
Nov 24, 2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, is pleased...
-
Nov 20, 2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today...